通过多层虚拟查来识别α2-上腺体受体的潜在激素类分子,以对抗鼻炎
Sobia Ahsan Halim1, Muhammad Waqas2, Ajmal Khan1
1Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al-Mouz, Nizwa, 616, Oman.
Computers in biology and medicine
|November 17, 2023
概括
针对α2-上腺素受体 (α2-AR) 的新药候选药物在治疗鼻炎方面表现有前途. 综合查确定了十个具有强大的结合亲和力的分子,为现有疗法提供了潜在的替代方案.
科学领域:
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
- 药物发现 药物发现 药物发现
背景情况:
- 鼻炎是一种普遍存在的呼吸道炎症疾病,影响全球数百万人,现有的治疗方法具有不良的副作用.
- 对于新型候选药物来有效管理鼻炎和减轻与治疗相关的不良影响,有极大的需求.
研究的目的:
- 为了识别和描述针对α2-上腺体受体 (α2-AR) 的新型药物样分子,用于潜在的鼻炎治疗.
- 评估已识别的化合物对α2-AR的结合亲和力和作用机制.
主要方法:
- 基于结构的内部化合物数据库的虚拟选,以识别α2-AR向分子.
- 分子动力学模拟和MM-PBSA计算以评估结合的自由能量和构造变化.
- 对物理化学性质和与关键α2-AR残留物结合相互作用的分析.
主要成果:
- 确定了10种类似药物的分子 (CP1-CP10),对α2-AR具有agonist作用.
- 化合物CP2,CP3,CP7,CP8和CP6表现出最高的结合自由能量,表明对α2-AR有很强的亲和力.
- 与已知的部分激动剂相比,鉴定的分子表现出有利的结合能,这表明其具有强大的治疗潜力.
结论:
- 这些已识别的分子显示出作为新药候选药物治疗鼻炎的巨大潜力.
- 这些化合物为开发针对α2-AR途径的新治疗策略提供了有前途的途径.
- 对这些分子的进一步研究可能会导致改善鼻炎的治疗,并减少副作用.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
13.7K
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
12.7K
相关概念视频
01:28Adrenergic Agonists: Mixed-Action Agents
745
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
745
01:25Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
01:30Adrenergic Agonists: Direct-Acting Agents
1.5K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.5K
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
885
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
885
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
01:18Adrenergic Agonists: Therapeutic Classification
830
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
830